[go: up one dir, main page]

MX2011012631A - Inhibidores de actividad de cinasa tipo pirimidina. - Google Patents

Inhibidores de actividad de cinasa tipo pirimidina.

Info

Publication number
MX2011012631A
MX2011012631A MX2011012631A MX2011012631A MX2011012631A MX 2011012631 A MX2011012631 A MX 2011012631A MX 2011012631 A MX2011012631 A MX 2011012631A MX 2011012631 A MX2011012631 A MX 2011012631A MX 2011012631 A MX2011012631 A MX 2011012631A
Authority
MX
Mexico
Prior art keywords
sup
kinase activity
compounds
pyrimidine inhibitors
pyrimidine
Prior art date
Application number
MX2011012631A
Other languages
English (en)
Inventor
Scott A Erickson
George S Sheppard
Jieyi Wang
Steve D Fidanze
Gary T Wang
Bryan K Sorensen
Richard F Clark
Randy L Bell
Robert A Mantei
Nwe Y Ba-Maung
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2011012631A publication Critical patent/MX2011012631A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula (I) o sales o solvatos farmacéuticamente aceptables de los mismos, en la cual G1, R2, R3, R4, R5, n, p, q, Ar1, y Ar2 se definen en la descripción. La presente invención también se refiere a métodos para elaborar dichos compuestos, y composiciones que comprenden dichos compuestos los cuales son útiles para inhibir cinasas tales como IGF-lR.
MX2011012631A 2009-05-27 2010-05-26 Inhibidores de actividad de cinasa tipo pirimidina. MX2011012631A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18156109P 2009-05-27 2009-05-27
PCT/US2010/036185 WO2010138576A1 (en) 2009-05-27 2010-05-26 Pyrimidine inhibitors of kinase activity

Publications (1)

Publication Number Publication Date
MX2011012631A true MX2011012631A (es) 2012-03-06

Family

ID=42352746

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012631A MX2011012631A (es) 2009-05-27 2010-05-26 Inhibidores de actividad de cinasa tipo pirimidina.

Country Status (8)

Country Link
US (1) US8354422B2 (es)
EP (1) EP2435436B1 (es)
JP (1) JP2012528175A (es)
CN (1) CN102459264A (es)
CA (1) CA2763631A1 (es)
ES (1) ES2520991T3 (es)
MX (1) MX2011012631A (es)
WO (1) WO2010138576A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8536180B2 (en) * 2009-05-27 2013-09-17 Abbvie Inc. Pyrimidine inhibitors of kinase activity
EP2402345A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazole fused bicyclic compounds
EP2402336A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
ES2715676T3 (es) * 2014-03-27 2019-06-05 Janssen Pharmaceutica Nv Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirazina sustituidos y derivados de 5,6,7,8-tetrahidro-4h-pirazolo[1,5-a][1,4]diazepina como inhibidores de ros1
WO2015144801A1 (en) * 2014-03-27 2015-10-01 Janssen Pharmaceutica Nv SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-b]PYRAZOLE DERIVATIVES AS ROS1 INHIBITORS
CN110526915B (zh) * 2018-05-25 2022-02-01 首药控股(北京)股份有限公司 一种间变性淋巴瘤激酶抑制剂的制备方法
CN110627775B (zh) * 2019-10-24 2026-01-30 特科罗生物科技(成都)有限公司 一种小分子化合物
UY38979A (es) 2019-12-06 2021-07-30 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio
TW202313593A (zh) 2021-06-04 2023-04-01 美商維泰克斯製藥公司 作為鈉通道調節劑之ｎ—（羥基烷基（雜）芳基）四氫呋喃甲醯胺
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CN118724764B (zh) * 2024-06-07 2025-11-18 绍兴文理学院 一种芳基伯磺酰胺类化合物的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215844D0 (en) * 2002-07-09 2002-08-14 Novartis Ag Organic compounds
EP1706400A1 (en) * 2004-01-09 2006-10-04 Novartis AG Phenyl- 4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl -amine derivatives as igf-ir inhibitors
WO2006068826A2 (en) * 2004-12-21 2006-06-29 Smithkline Beecham Corporation 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
US8211929B2 (en) 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US7807673B2 (en) * 2005-12-05 2010-10-05 Glaxosmithkline Llc 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
WO2008150799A1 (en) * 2007-06-01 2008-12-11 Smithkline Beecham Corporation Imidazopyridine kinase inhibitors

Also Published As

Publication number Publication date
ES2520991T3 (es) 2014-11-12
WO2010138576A1 (en) 2010-12-02
CN102459264A (zh) 2012-05-16
CA2763631A1 (en) 2010-12-02
JP2012528175A (ja) 2012-11-12
EP2435436A1 (en) 2012-04-04
US20100305126A1 (en) 2010-12-02
US8354422B2 (en) 2013-01-15
EP2435436B1 (en) 2014-07-30

Similar Documents

Publication Publication Date Title
MX2011012631A (es) Inhibidores de actividad de cinasa tipo pirimidina.
MX2011012629A (es) Inhibidores de actividad de cinasa tipo pirimidina.
MX2011013325A (es) 2-(lh-pirazol-4-ilamino)-pirimidina como inhibidores de cinasa.
MX2012013197A (es) Inhibidores de indazol de cinasa.
MX2011012632A (es) Inhibidores de actividad de cinasa tipo pirimidina.
MX2012000711A (es) Inhibidores de pirrolopirazina de cinasas.
MY148634A (en) Pyridazinone derivatives
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
MX336726B (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.
MX2008005398A (es) Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer.
MX2013001361A (es) 4-(1h-indol-3-il) - pirimidina como inhibidores de alk.
MX2009013077A (es) Derivados dde benzoxazolona.
GEP20125564B (en) Pyrimidine derivatives as kinase inhibitors
JO3181B1 (ar) مشتقات كمحول ثاني الكيل البايردينيل - أحادي الفينيل كأنزيم ثنائي استرات الفوسفود
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2013009873A (es) Inhibidores triciclicos de cinasas.
MX2009010595A (es) Derivados de pirrolopirimidina.
TW201713640A (en) Bruton's tyrosine kinase inhibitors
MX2010003685A (es) Analogos de quinolona y metodos relacionados con los mismos.
UA101057C2 (en) Pyrimidine derivatives as kinase inhibitors
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ABBVIE INC.

FG Grant or registration